MELVILLE, N.Y., July 11, 2017 -- North American Partners in Anesthesia (NAPA), one of the leading single-specialty anesthesia and perioperative management companies in the US, today announced that Victor Zamora has joined the organization as Senior Vice President, Revenue Cycle Management. In this capacity, Mr. Zamora will be responsible for providing strategic direction, guidance and operational performance for all revenue cycle functions, including departmental infrastructure, reporting and service development. He brings over 18 years of experience in providing revenue cycle transformation services for both acute care and physician-based organizations.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/af70c6c5-b518-462b-99e5-0396c171b7be
“With the addition of Mr. Zamora to our team, NAPA is furthering its commitment to help its clients navigate the complex and evolving regulations of healthcare,” said John F. Di Capua, MD, CEO of NAPA. “Mr. Zamora’s vast experience and demonstrated success within the healthcare industry will have a significant impact on strengthening NAPA’s RCM expertise and generating greater alignment across our financial operations to effectively advance our capabilities and service offerings.”
“I’m extremely excited to be joining a dynamic organization like NAPA," said Mr. Zamora. “As we continue to rapidly move to a value-based arena, it is essential we look at RCM in a new way to measure and achieve success. I’m always looking for opportunities to improve performance and look forward to working with NAPA’s dedicated RCM team to elevate the organization in meeting the unique needs of its growing client network while delivering improved financial outcomes.”
Prior to joining the organization, Mr. Zamora held several revenue cycle leadership positions, applying his experience by implementing process improvement and cash acceleration initiatives at acute care organizations, federally-qualified health centers, multi-specialty groups, surgical centers and small to moderately-sized physician groups. Most recently, Mr. Zamora served as Vice President of Accounts Receivable Services for MedAssets.
About North American Partners in Anesthesia
As a clinician-led organization, North American Partners in Anesthesia (NAPA) is redefining healthcare, delivering unsurpassed excellence to its partners and patients every day. In three decades, NAPA has grown to become the nation’s leading single-specialty anesthesia and perioperative management company, serving more than one million patients annually in more than 200 healthcare facilities throughout the Northeast, Mid-Atlantic, Midwest and Southeast. For more information, visit NAPAanesthesia.com.
Media Contact Jill Hoenigmann, Marketing Manager North American Partners in Anesthesia P: (516) 945-3030 E: [email protected]


Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 



